Monday, 2 December 2013

3 December, 2013

Aspirin could prevent dementia and cancer!

Aspirin is generally known to be useful in preventing heart attacks and strokes, but now researchers believe the humble aspirin could also hold the key to warding off dementia and cancer. The claim has been made at the launch of the largest ever study into the health benefits of the everyday medicine, which has long been thought of as a health-booster.
A study of 15,000 people aged over 70 will be the most extensive clinical trial on the use of aspirin to prevent disease in the elderly, Daily Mail reported. Research team leader Mark Nelson, from Hobart’s Menzies Research Institute in Tasmania, Australia, said: “Remember aspirin is an over-the-counter medication; you don’t need a doctor to prescribe it, you don’t need a doctor to tell you you’ve turned 70. So this is something that can be done very simply, very cheaply if we find that it’s an effective strategy.”
Nelson said the study starts next summer and results are expected in 2018. Millions of people who take the pill to fight heart disease or the risk of a stroke benefit from its effectiveness at thinning the blood and how it helps to prevent clotting. It cuts the danger of further heart attacks or strokes by at least 23 per cent. Research has shown regular users have a lower risk of developing Alzheimer’s disease, the main form of dementia. Scientists believe its protective effect may be due to its anti-clotting action helping blood flow to the brain.
Research has also shown that aspirin may have a role in fighting cancer, particularly gastro-intestinal cancers. ”Now that makes sense because you take it orally so in aspirin you’ve got that natural component.” In the study – in the journal Contemporary Clinical Trials – the team wants to establish whether the benefits of a low dose of aspirin outweigh the risks linked to its use.
03.12.2013



Beware – energy drinks spike your heart rate!

Scientists have revealed that healthy adults who consume energy drinks with high caffeine and taurine content have significantly increased heart contraction rates one hour later. Jonas Dorner, M.D., radiology resident of the cardiovascular imaging section at the University of Bonn, Germany said that they haven’t known exactly what effect these energy drinks have on the function of the heart.
Doner said that there are concerns about the beverage’s potential adverse side effects on heart function, especially in adolescents and young adults, but there is little or no regulation of energy drink sales. He said that usually energy drinks contain taurine and caffeine as their main pharmacological ingredients and the amount of caffeine is up to three times higher than in other caffeinated beverages like coffee or cola. There are many side effects known to be associated with a high intake of caffeine, including rapid heart rate, palpitations, rise in blood pressure and, in the most severe cases, seizures or sudden death. 
In the ongoing study, Dorner and his colleagues have used cardiac magnetic resonance imaging (MRI) to measure the effect of energy drink consumption on heart function in 18 healthy volunteers, including 15 men and three women with a mean age of 27.5 years. Each of the volunteers underwent cardiac MRI before and one hour after consuming an energy drink containing taurine (400 mg/100 ml) and caffeine (32 mg/100 ml).
The research saw that as compared to the baseline images, MRI performed one hour after the study participants consumed the energy drink revealed significantly increased peak strain and peak systolic strain rates in the left ventricle of their heart. However, the researchers have found no significant differences in heart rate, blood pressure or the amount of blood ejected from the left ventricle of the heart between the volunteers’ baseline and second MRI exams. The study was presented at the annual meeting of the Radiological Society of North America.
03.12.2013



 

 

 

 

 

Do your work with your whole heart, and you will succeed – there’s so little competition

Elbert Hubbard



No comments:

Post a Comment